S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
66,000% upside on tiny biotech? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
66,000% upside on tiny biotech? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
66,000% upside on tiny biotech? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
66,000% upside on tiny biotech? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
66,000% upside on tiny biotech? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
66,000% upside on tiny biotech? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
66,000% upside on tiny biotech? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
66,000% upside on tiny biotech? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
NASDAQ:HSKA

Heska (HSKA) Stock Forecast, Price & News

$119.84
-0.01 (-0.01%)
(As of 06/2/2023 ET)
Compare
Today's Range
$119.82
$119.86
50-Day Range
$92.52
$119.85
52-Week Range
$57.83
$119.90
Volume
374,623 shs
Average Volume
230,295 shs
Market Capitalization
$1.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$137.25

Heska MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
14.5% Upside
$137.25 Price Target
Short Interest
Bearish
10.55% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.82mentions of Heska in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
220.00%
From $0.45 to $1.44 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.85 out of 5 stars

Medical Sector

755th out of 983 stocks

Diagnostic Substances Industry

10th out of 15 stocks


HSKA stock logo

About Heska (NASDAQ:HSKA) Stock

Heska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. It operates through the North America and International segments. The North America segment includes the United States, Canada, and Mexico. The International segment involves Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company was founded by Robert B. Grieve and Lynnor B. Stevenson in 1988 and is headquartered in Loveland, CO.

Receive HSKA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heska and its competitors with MarketBeat's FREE daily newsletter.

HSKA Stock News Headlines

Heska (NASDAQ:HSKA) Coverage Initiated at StockNews.com
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
Heska (NASDAQ:HSKA) Now Covered by Analysts at StockNews.com
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Heska (NASDAQ:HSKA) Downgraded by Alliance Global Partners
Morgan Stanley Upgrades Heska (NASDAQ:HSKA) to Equal Weight
Why Heska Stock Is On Fire Today
Heska (HSKA) Moves to Buy: Rationale Behind the Upgrade
See More Headlines

HSKA Price History

HSKA Company Calendar

Last Earnings
11/04/2021
Today
6/03/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HSKA
Employees
655
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$137.25
High Stock Price Forecast
$150.00
Low Stock Price Forecast
$120.00
Forecasted Upside/Downside
+14.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-19,890,000.00
Pretax Margin
-7.91%

Debt

Sales & Book Value

Annual Sales
$257.31 million
Cash Flow
$1.69 per share
Book Value
$38.27 per share

Miscellaneous

Free Float
9,572,000
Market Cap
$1.31 billion
Optionable
Not Optionable
Beta
1.58

Key Executives

  • Kevin S. WilsonKevin S. Wilson
    President, Chief Executive Officer & Director
  • Catherine I. GrassmanCatherine I. Grassman
    Chief Financial Officer & Executive Vice President
  • Glenn R. Frank
    Vice President-Research & Development
  • Steven M. Eyl
    Chief Commercial Officer & Executive VP
  • Eleanor F. Baker
    Executive Vice President & Managing Director













HSKA Stock - Frequently Asked Questions

Should I buy or sell Heska stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Heska in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HSKA shares.
View HSKA analyst ratings
or view top-rated stocks.

What is Heska's stock price forecast for 2023?

4 brokers have issued 1-year price targets for Heska's stock. Their HSKA share price forecasts range from $120.00 to $150.00. On average, they predict the company's stock price to reach $137.25 in the next year. This suggests a possible upside of 14.5% from the stock's current price.
View analysts price targets for HSKA
or view top-rated stocks among Wall Street analysts.

How have HSKA shares performed in 2023?

Heska's stock was trading at $62.16 on January 1st, 2023. Since then, HSKA stock has increased by 92.8% and is now trading at $119.84.
View the best growth stocks for 2023 here
.

Are investors shorting Heska?

Heska saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,060,000 shares, an increase of 24.6% from the April 30th total of 850,800 shares. Based on an average daily volume of 266,700 shares, the short-interest ratio is currently 4.0 days. Currently, 10.6% of the shares of the stock are sold short.
View Heska's Short Interest
.

When is Heska's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our HSKA earnings forecast
.

How were Heska's earnings last quarter?

Heska Co. (NASDAQ:HSKA) announced its quarterly earnings data on Thursday, November, 4th. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by $0.23. The medical research company had revenue of $60.24 million for the quarter, compared to analysts' expectations of $63.80 million. Heska had a positive trailing twelve-month return on equity of 0.94% and a negative net margin of 7.86%. The company's revenue was up 6.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.25) EPS.

What is Kevin S. Wilson's approval rating as Heska's CEO?

5 employees have rated Heska Chief Executive Officer Kevin S. Wilson on Glassdoor.com. Kevin S. Wilson has an approval rating of 57% among the company's employees. This puts Kevin S. Wilson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Heska own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Gilead Sciences (GILD), Exxon Mobil (XOM), Netflix (NFLX), Biogen (BIIB), AbbVie (ABBV), Amgen (AMGN), Broadcom (AVGO), Alibaba Group (BABA), Exelixis (EXEL) and Merck & Co., Inc. (MRK).

What is Heska's stock symbol?

Heska trades on the NASDAQ under the ticker symbol "HSKA."

Who are Heska's major shareholders?

Heska's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (17.20%), Fred Alger Management LLC (7.59%), Ameriprise Financial Inc. (5.29%), State Street Corp (3.98%), abrdn plc (3.35%) and Riverbridge Partners LLC (2.83%). Insiders that own company stock include Bonnie J Trowbridge, Catherine Grassman, Jason D Aroesty, Kevin S Wilson, Nancy Wisnewski and Sharon J Larson.
View institutional ownership trends
.

How do I buy shares of Heska?

Shares of HSKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Heska's stock price today?

One share of HSKA stock can currently be purchased for approximately $119.84.

How much money does Heska make?

Heska (NASDAQ:HSKA) has a market capitalization of $1.31 billion and generates $257.31 million in revenue each year. The medical research company earns $-19,890,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.

How many employees does Heska have?

The company employs 655 workers across the globe.

How can I contact Heska?

Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The official website for the company is www.heska.com. The medical research company can be reached via phone at (970) 493-7272, via email at investorrelations@heska.com, or via fax at 970-619-3003.

This page (NASDAQ:HSKA) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -